Akari Therapeutics (AKTX)
NASDAQ: AKTX
· Real-Time Price · USD
1.00
0.03 (3.08%)
At close: Aug 15, 2025, 3:58 PM
1.00
0.00%
After-hours: Aug 15, 2025, 04:10 PM EDT
Akari Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 13K | n/a | n/a | n/a | 1K | n/a | n/a | 942.00 | 1.01K | 1.01K | 1.03K | 1.05K | 1.03K |
Gross Profit | n/a | n/a | n/a | n/a | -13K | n/a | n/a | n/a | -1K | n/a | n/a | -942 | -1.01K | -1.01K | -1.03K | -1.05K | n/a |
Operating Income | -3.52M | -5.28M | -2.93M | -7.45M | -5.99M | -3.8M | -3.8M | -9.21M | -4.59M | -6.01M | -6.01M | -5.82M | -5.24M | -5.87M | -1.46M | -4.33M | -5.55M |
Interest Income | n/a | 1K | 3K | 2K | 2K | 11.45 | n/a | 59.06K | 30K | 18.81 | 18.81 | 3.96K | 4.36K | 3.98K | 1.37K | 1.51K | 3.73K |
Pretax Income | -3.71M | -3.77M | -2.9M | -7.56M | -5.57M | -3.5M | -3.5M | -3M | 1M | -3.45M | -3.45M | -5.68M | -5.18M | -5.79M | -1.45M | -4.35M | -5.84M |
Net Income | -3.71M | -3.77M | -2.9M | -7.56M | -5.57M | -3.5M | -3.5M | -3M | 1M | -3.45M | -3.45M | -5.54M | -5.11M | -5.61M | -1.43M | -4.38M | -5.84M |
Selling & General & Admin | 2.71M | 3.05M | 1.71M | 2.24M | 3.7M | 2.7M | 2.7M | 5.95M | 2.86M | 3.73M | 3.73M | 2.97M | 3.1M | 2.02M | 1.89M | 2.15M | 2.02M |
Research & Development | 813K | 1.25M | 143K | 3.31M | 2.28M | 4.44M | 4.44M | 3.25M | 1.73M | 3.44M | 3.44M | 2.85M | 2.14M | 3.85M | -430.16K | 2.18M | 3.53M |
Other Expenses | n/a | 983K | 1.07M | n/a | -2 | n/a | n/a | -22.81K | -11 | n/a | n/a | -9.21K | -7.11K | -11.12K | -3.55K | -5.09K | n/a |
Operating Expenses | 3.52M | 5.28M | 2.93M | 5.55M | 5.98M | 3.52M | 3.52M | 9.21M | 4.59M | 3.46M | 3.46M | 5.82M | 5.24M | 5.87M | 1.46M | 4.33M | 5.55M |
Interest Expense | 55K | 124K | 69K | 51K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 3.69M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.52M | 5.28M | 2.93M | 7.45M | 5.99M | 3.52M | 3.52M | 9.21M | 4.59M | 3.46M | 3.46M | 5.82M | 5.24M | 5.87M | 1.46M | 4.33M | 5.55M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -0.00 | -0.00 | n/a | n/a | -136.17K | -67.59K | -175.19K | -26.27K | 29.09K | n/a |
Shares Outstanding (Basic) | 272.00 | 11.94K | 12.19K | 9.42K | 6.73K | 5.39K | 5.06K | 5.06K | 3.74K | 3.42K | 3.42K | 2.97K | 2.68K | 2.41K | 2.32K | 1.92K | 1.92K |
Shares Outstanding (Diluted) | 272.00 | 11.94K | 12.19K | 9.42K | 6.73K | 5.39K | 5.06K | 5.06K | 3.79K | 3.42K | 3.42K | 2.97K | 2.68K | 2.41K | 2.32K | 1.92K | 1.92K |
EPS (Basic) | -13.58K | -40 | -20 | -80 | -80 | -60 | -60 | -60 | 20.00 | -100 | -100 | -180 | -200 | -240 | -60 | -220 | -300 |
EPS (Diluted) | -13.58K | -40 | -20 | -80 | -80 | -60 | -60 | -60 | 20.00 | -100 | -100 | -180 | -200 | -240 | -60 | -220 | -300 |
EBITDA | -3.65M | -3.65M | -2.93M | -7.51M | -5.98M | -3.8M | -3.8M | -4M | -4.59M | -6.01M | -6.01M | -5.82M | -5.24M | -5.87M | -1.46M | -4.33M | -5.55M |
EBIT | -3.65M | -3.65M | -2.83M | -7.51M | -5.99M | -3.8M | -3.8M | -4M | -4.59M | -6.01M | -6.01M | -5.82M | -5.24M | -5.87M | -1.46M | -4.33M | -5.55M |
Depreciation & Amortization | n/a | 1K | n/a | -58K | 13K | 1.07K | 1.07K | 1.85K | 1K | 1.03K | 1.03K | 942.00 | 1.01K | 1.01K | 1.03K | 1.05K | 1.03K |